<DOC>
	<DOCNO>NCT00002911</DOCNO>
	<brief_summary>RATIONALE : Marimastat may stop growth non-small cell lung cancer stop blood flow tumor . PURPOSE : Randomized double-blinded phase III trial determine effectiveness marimastat treat patient residual stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Marimastat Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect marimastat ( matrix metalloproteinase inhibitor ) vs. placebo overall survival patient Stage III non-small cell lung cancer minimal residual disease follow chemotherapy , radiotherapy , and/or surgery . II . Assess effect marimastat time disease progression patient . III . Assess safety tolerability marimastat patient . OUTLINE : This randomize , double-blind study . Patients randomize less 2 8 week last prior treatment modality receive . Patients stratify participate institution . Patients randomly assign receive either oral marimastat oral placebo twice daily . Treatment begin within 5 day minimization continue 18 month last patient enrol , unless disease progression unacceptable toxicity intervenes . Patients derive benefit end study may continue treatment desire . Patients follow every 3 month . PROJECTED ACCRUAL : A total 504 patient enter 30 month approximately 60 center .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Marimastat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage IIIA/B disease No malignant pleural effusion Minimal residual disease one combination follow : Incomplete surgical resection i.e. , macroscopic residual disease completion surgery Radical radiotherapy evidence disease progression entry Documented complete partial tumor response follow least 2 course cytotoxic chemotherapy No evidence disease progression follow prior therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : Absolute neutrophil count great 500/mm3 Platelet count great 50,000/mm3 Hepatic : Bilirubin le 2.0 time upper limit normal ( ULN ) AST/ALT great 3.0 time ULN Renal : Creatinine great 1.5 time ULN Other : No acute illness within 1 week start study No illness would significantly interfere study outcome No major medical illness precludes prolong marimastat administration No second malignancy within 5 year except : Adequately treat basal cell carcinoma skin In situ carcinoma cervix Not pregnant nursing Medically approve method contraception require fertile woman Willing able tolerate comply study requirement PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior marimastat , batimastat , bleomycin , busulphan No 1 cytotoxic chemotherapy regimen nonsmall cell lung cancer Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : At least 4 week since investigational drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>